Targeting carbonic anhydrases for the management of hypoxic metastatic tumors

References

• Aspatwar A, Tolvanen MEE, Barker H, et al. Carbonic anhydrases in metazoan model organisms: molecules, mechanisms, and physiology. Physiol Rev. 2022;102(3):1327–1383. doi: 10.1152/physrev.00018.2021
   PubMed Web of Science ®Google Scholar
• Smith KS, Jakubzick C, Whittam TS, et al. Carbonic anhydrase is an ancient enzyme widespread in prokaryotes. Proc Natl Acad Sci U S A. 1999;96(26):15184–15189. doi: 10.1073/pnas.96.26.15184
   PubMed Web of Science ®Google Scholar
• Ueda K, Nishida H, Beppu T. Dispensabilities of carbonic anhydrase in proteobacteria. Int J Evol Biol. 2012;2012:1–5. doi: 10.1155/2012/324549
   Google Scholar
• Capasso C, Supuran CT. An overview of the alpha-, beta- and gamma-carbonic anhydrases from Bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria? J Enzyme Inhib Med Chem. 2015;30(2):325–332. doi: 10.3109/14756366.2014.910202
   PubMed Web of Science ®Google Scholar
• Nocentini A, Supuran CT, Capasso C. An overview on the recently discovered iota-carbonic anhydrases. J Enzyme Inhib Med Chem. 2021;36(1):1988–1995. doi: 10.1080/14756366.2021.1972995
   PubMed Web of Science ®Google Scholar
• Supuran CT. Structure and function of carbonic anhydrases. Biochem J. 2016;473(14):2023–2032. doi: 10.1042/BCJ20160115
   PubMed Web of Science ®Google Scholar
• Pastorek J, Pastoreková S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene. 1994;9:2877–2888.
   PubMed Web of Science ®Google Scholar
• Türeci O, Sahin U, Vollmar E, et al. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc Natl Acad Sci U S A. 1998;95(13):7608–7613. doi: 10.1073/pnas.95.13.7608
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 2011;10(10):767–777. doi: 10.1038/nrd3554
   PubMed Web of Science ®Google Scholar
• Semenza GL. Pharmacologic targeting of hypoxia-inducible factors. Annu Rev Pharmacol Toxicol. 2019;59(1):379–403. doi: 10.1146/annurev-pharmtox-010818-021637
   PubMedGoogle Scholar
• Kaelin WJ. The vhl tumor suppressor gene: insights into oxygen sensing and cancer. Trans Am Clin Climatol Assoc. 2017;128:298–307. doi: 10.1053/j.ajkd.2016.12.011
   PubMedGoogle Scholar
• Pugh CW, Ratcliffe PJ. New horizons in hypoxia signaling pathways. Exp Cell Res. 2017;356(2):116–121. doi: 10.1016/j.yexcr.2017.03.008
   PubMed Web of Science ®Google Scholar
• Pettersen EO, Ebbesen P, Gieling RG, et al. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem. 2015;30(5):689–721. doi: 10.3109/14756366.2014.966704
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000;60:7075–7083.
   PubMed Web of Science ®Google Scholar
• Svastová E, Hulíková A, Rafajová M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004;577(3):439–445. doi: 10.1016/j.febslet.2004.10.043
   PubMed Web of Science ®Google Scholar
• Dubois L, Douma K, Supuran CT, et al. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol. 2007;83(3):367–373. doi: 10.1016/j.radonc.2007.04.018
   PubMed Web of Science ®Google Scholar
• Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 2011;71(9):3364–3376. doi: 10.1158/0008-5472.CAN-10-4261
   PubMed Web of Science ®Google Scholar
• Gieling RG, Babur M, Mamnani L, et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem. 2012;55(11):5591–5600. doi: 10.1021/jm300529u
   PubMed Web of Science ®Google Scholar
• Ahlskog JK, Dumelin CE, Trüssel S, et al. In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg Med Chem Lett. 2009;19(16):4851–4856. doi: 10.1016/j.bmcl.2009.06.022
   PubMed Web of Science ®Google Scholar
• Lock FE, McDonald PC, Lou Y, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene. 2013 Oct 31;32(44):5210–5219. doi: 10.1038/onc.2012.550
   PubMed Web of Science ®Google Scholar
• Supuran CT, Alterio V, Di Fiore A, et al. Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: Three for the price of one. Med Res Rev. 2018;38(6):1799–1836. doi: 10.1002/med.21497
   PubMed Web of Science ®Google Scholar
• McDonald PC, Chafe SC, Supuran CT, et al. Cancer therapeutic targeting of hypoxia induced carbonic anhydrase ix: from bench to bedside. Cancers (Basel). 2022;14(14):3297. doi: 10.3390/cancers14143297
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs. 2018;27(12):963–970. doi: 10.1080/13543784.2018.1548608
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs. 2021;30(12):1197–1208. doi: 10.1080/13543784.2021.2014813
   PubMed Web of Science ®Google Scholar
• Angeli A, Carta F, Nocentini A, et al. Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment. Metabolites. 2020;10(10):412. doi: 10.3390/metabo10100412
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Gillies RJ. The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev. 2019;38(1–2):65–77. doi: 10.1007/s10555-019-09799-0
   PubMed Web of Science ®Google Scholar
• Nocentini A, Supuran CT. Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018). Expert Opin Ther Pat. 2018;28(10):729–740. doi: 10.1080/13543776.2018.1508453
   PubMed Web of Science ®Google Scholar
• Nerella SG, Singh P, Arifuddin M, et al. Anticancer carbonic anhydrase inhibitors: a patent and literature update 2018-2022. Expert Opin Ther Pat. 2022;32(8):833–847. doi: 10.1080/13543776.2022.2083502
   PubMed Web of Science ®Google Scholar
• Supuran CT. Latest advances in specific inhibition of tumor-associated carbonic anhydrases. Future Med Chem. 2023;15(1):5–7. doi: 10.4155/fmc-2022-0249
   PubMed Web of Science ®Google Scholar
• Pastoreková S, Pastorek J. Cancer-related carbonic anhydrase isozymes and their inhibition. In: Supuran C, Scozzafava A, and Conway J, editors. Carbonic anhydrase – its inhibitors and activators. Boca Raton (FL): CRC Press; 2004. p. 255–281. doi: 10.1201/9780203475300.ch9
   Google Scholar
• Supuran CT. Emerging role of carbonic anhydrase inhibitors. Clin Sci. 2021;135(10):1233–1249. doi: 10.1042/CS20210040
   PubMed Web of Science ®Google Scholar
• Saarnio J, Parkkila S, Parkkila AK, et al. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol. 1998;153(1):279–285. doi: 10.1016/S0002-9440(10)65569-1
   PubMed Web of Science ®Google Scholar
• Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle. 2004;3(2):164–167. doi: 10.4161/cc.3.2.618
   PubMed Web of Science ®Google Scholar
• Haapasalo JA, Nordfors KM, Hilvo M, et al. Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res. 2006;12(2):473–477. doi: 10.1158/1078-0432.CCR-05-0848
   PubMed Web of Science ®Google Scholar
• Takacova M, Bartosova M, Skvarkova L, et al. Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma. Oncol Lett. 2013;5(1):191–197. doi: 10.3892/ol.2012.1001
   PubMed Web of Science ®Google Scholar
• Viikilä P, Kivelä AJ, Mustonen H, et al. Carbonic anhydrase enzymes II, VII, IX and XII in colorectal carcinomas. World J Gastroenterol. 2016;22(36):8168–8177. doi: 10.3748/wjg.v22.i36.8168
   PubMed Web of Science ®Google Scholar
• Parkkila S, Lasota J, Fletcher JA, et al. Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. Mod Pathol. 2010;23(5):743–750. doi: 10.1038/modpathol.2009.189
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Harris AL, Banham AH, et al. Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration. Br J Cancer. 2020;122(8):1205–1210. doi: 10.1038/s41416-020-0756-3
   PubMed Web of Science ®Google Scholar
• Haapasalo J, Nordfors K, Haapasalo H, et al. The expression of carbonic anhydrases ii, ix and xii in brain tumors. Cancers (Basel). 2020;12(7):1723. doi: 10.3390/cancers12071723
   PubMed Web of Science ®Google Scholar
• Li G, Chen TW, Nickel AC, et al. Carbonic anhydrase xii is a clinically significant, molecular tumor-subtype specific therapeutic target in glioma with the potential to combat invasion of brain tumor cells. Onco Targets Ther. 2021;14:1707–1718. DOI:10.2147/OTT.S300623
   PubMed Web of Science ®Google Scholar
• Nortunen M, Parkkila S, Saarnio J, et al. Carbonic anhydrases ii and ix in non-ampullary duodenal adenomas and adenocarcinoma. J Histochem Cytochem. 2021;69(11):677–690. doi: 10.1369/00221554211050133
   PubMed Web of Science ®Google Scholar
• Rezuchova I, Bartosova M, Belvoncikova P, et al. Carbonic anhydrase ix in tumor tissue and plasma of breast cancer patients: reliable biomarker of hypoxia and prognosis. Int J Mol Sci. 2023;24(5):4325. doi: 10.3390/ijms24054325
   PubMed Web of Science ®Google Scholar
• Shamis SAK, Edwards J, McMillan DC. The relationship between carbonic anhydrase IX (CAIX) and patient survival in breast cancer: systematic review and meta-analysis. Diagn Pathol. 2023;18(1):46. doi: 10.1186/s13000-023-01325-9
   PubMed Web of Science ®Google Scholar
• Numprasit W, Yangngam S, Prasopsiri J, et al. Carbonic anhydrase IX-related tumoral hypoxia predicts worse prognosis in breast cancer: A systematic review and meta-analysis. Front Med. 2023;10:1087270. DOI:10.3389/fmed.2023.1087270
   Web of Science ®Google Scholar
• Bádon ES, Beke L, Mokánszki A, et al. Carbonic anhydrase ix expression and treatment response measured in rectal adenocarcinoma following neoadjuvant chemo-radiotherapy. Int J Mol Sci. 2023;24(3):2581. doi: 10.3390/ijms24032581
   PubMed Web of Science ®Google Scholar
• Xiang AP, Chen XN, Xu PF, et al. Expression and prognostic value of carbonic anhydrase IX (CA-IX) in bladder urothelial carcinoma. BMC Urol. 2022;22(1):120. doi: 10.1186/s12894-022-01074-9
   PubMed Web of Science ®Google Scholar
• Hiepp L, Mayr D, Gärtner K, et al. Carbonic anhydrase XII as biomarker and therapeutic target in ovarian carcinomas. PLoS One. 2022;17(7):e0271630. doi: 10.1371/journal.pone.0271630
   PubMed Web of Science ®Google Scholar
• Shamis SAK, Quinn J, Mallon EEA, et al. The relationship between the tumor cell expression of hypoxic markers and survival in patients with er-positive invasive ductal breast cancer. J Histochem Cytochem. 2022;70(7):479–494. doi: 10.1369/00221554221110280
   PubMed Web of Science ®Google Scholar
• Xu B, Lou Y, Xu X, et al. Carbonic anhydrase 4 serves as a novel prognostic biomarker and therapeutic target for non-small cell lung cancer: a study based on TCGA samples. Comb Chem High Throughput Screen. 2023. in press. doi: 10.2174/1386207326666230321091943
   Web of Science ®Google Scholar
• Fei L, Cantini G, Nocentini A, et al. Carbonic anhydrases III and IX are new players in the crosstalk between adrenocortical carcinoma and its altered adipose microenvironment. J Endocrinol Invest. 2023;46(7):1449–1458. doi: 10.1007/s40618-023-02008-4
   PubMed Web of Science ®Google Scholar
• Chen F, Licarete E, Wu X, et al. Pharmacological inhibition of carbonic anhydrase IX and XII to enhance targeting of acute myeloid leukaemia cells under hypoxic conditions. J Cell Mol Med. 2021;25(24):11039–11052. doi: 10.1111/jcmm.17027
   PubMed Web of Science ®Google Scholar
• Alyaqubi KJ, Dosh RH, Al-Fatlawi RB, et al. Gene expression of carbonic anhydrase 9 (CA9) in de novo acute leukemia as a predictive marker for prognosis. J Med Life. 2022;15(9):1158–1163. doi: 10.25122/jml-2021-0212
   PubMedGoogle Scholar
• Romeo PH, Lewandowski D, Barroca V, et al. Carbonic anhydrase 1 (CA1) inhibitors for the treatment or prevention of myeloproliferative disorders and other hematopoietic malignancies, and as biomarker of myeloproliferative disorders and other hematopoietic malignancies. EP4062909A1. 2022.
   Google Scholar
• Murakami S, Barroca V, Perié L, et al. In Vivo monitoring of polycythemia vera development reveals carbonic anhydrase 1 as a potent therapeutic target. Blood Cancer Discov. 2022;3(4):285–297. doi: 10.1158/2643-3230.BCD-21-0039
   PubMedGoogle Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7(2):168–181. doi: 10.1038/nrd2467
   PubMed Web of Science ®Google Scholar
• Demandt JAF, Dubois LJ, van Kuijk K, et al. The hypoxia-sensor carbonic anhydrase IX affects macrophage metabolism, but is not a suitable biomarker for human cardiovascular disease. Sci Rep. 2021;11(1):425. doi: 10.1038/s41598-020-79978-5
   PubMed Web of Science ®Google Scholar
• Zatovicova M, Kajanova I, Takacova M, et al. ADAM10 mediates shedding of carbonic anhydrase IX ectodomain non‑redundantly to ADAM17. Oncol Rep. 2023;49(2):27. doi: 10.3892/or.2022.8464
   PubMed Web of Science ®Google Scholar
• Logozzi M, Capasso C, Di Raimo R, et al. Prostate cancer cells and exosomes in acidic condition show increased carbonic anhydrase IX expression and activity. J Enzyme Inhib Med Chem. 2019;34(1):272–278. doi: 10.1080/14756366.2018.1538980
   PubMed Web of Science ®Google Scholar
• Logozzi M, Mizzoni D, Capasso C, et al. Plasmatic exosomes from prostate cancer patients show increased carbonic anhydrase IX expression and activity and low pH. J Enzyme Inhib Med Chem. 2020;35(1):280–288. doi: 10.1080/14756366.2019.1697249
   PubMed Web of Science ®Google Scholar
• Venturella M, Falsini A, Coppola F, et al. CA-IX-Expressing Small Extracellular Vesicles (sEvs) are released by melanoma cells under hypoxia and in the blood of advanced melanoma patients. Int J Mol Sci. 2023;24(7):6122. doi: 10.3390/ijms24076122
   PubMed Web of Science ®Google Scholar
• Salciccia S, Frisenda M, Bevilacqua G, et al. Exosome analysis in prostate cancer: how they can improve biomarkers. Perf Curr Issues Mol Biol. 2023;45(7):6085–6096. doi: 10.3390/cimb45070384
   PubMed Web of Science ®Google Scholar
• Zatovicova M, Jelenska L, Hulikova A, et al. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr Pharm Des. 2010;16(29):3255-63–. doi: 10.2174/138161210793429832
   PubMed Web of Science ®Google Scholar
• Lam JS, Pantuck AJ, Belldegrun AS, et al. G250: a carbonic anhydrase IX monoclonal antibody. Curr Oncol Rep. 2005;7(2):109–115. doi: 10.1007/s11912-005-0036-7
   PubMedGoogle Scholar
• Zatovicova M, Jelenska L, Hulikova A, et al. Monoclonal antibody G250 targeting CA Ⅸ: binding specificity, internalization and therapeutic effects in a non-renal cancer model. Int J Oncol. 2014;45(6):2455–2467. doi: 10.3892/ijo.2014.2658
   PubMed Web of Science ®Google Scholar
• Tataru OS, Marchioni M, Crocetto F, et al. Molecular imaging diagnosis of renal cancer using 99mTc-Sestamibi SPECT/CT and girentuximab PET-ct-current evidence and future development of novel techniques. Diagnostics. 2023;13(4):593. doi: 10.3390/diagnostics13040593
   Web of Science ®Google Scholar
• Verhoeff SR, Oosting SF, Elias SG, et al. [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to predict watchful waiting duration in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res. 2023;29(3):592–601. doi: 10.1158/1078-0432.CCR-22-0921
   PubMed Web of Science ®Google Scholar
• Al-Zubaidi M, Viswambaram P, McCombie S, et al. 89Zirconium-labelled girentuximab (89Zr-TLX250) PET in urothelial cancer patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma. BMJ Open. 2022;12(4):e060478. doi: 10.1136/bmjopen-2021-060478
   PubMed Web of Science ®Google Scholar
• van Oostenbrugge T, Mulders P. Targeted PET/CT imaging for clear cell renal cell carcinoma with radiolabeled antibodies: recent developments using girentuximab. Curr Opin Urol. 2021;31(3):249–254. doi: 10.1097/MOU.0000000000000872
   PubMed Web of Science ®Google Scholar
• van Oostenbrugge TJ, Langenhuijsen JF, Oosterwijk E, et al. Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with 111In-girentuximab. Eur J Nucl Med Mol Imaging. 2020;47(8):1864–1870. doi: 10.1007/s00259-019-04613-z
   PubMed Web of Science ®Google Scholar
• ClinicalTrials. gov Identifier: NCT05239533 and ClinicalTrials.gov Identifier: NCT00087022
   Google Scholar
• Takacova M, Kajanova I, Kolarcikova M, et al. Understanding metabolic alterations and heterogeneity in cancer progression through validated immunodetection of key molecular components: a case of carbonic anhydrase IX. Cancer Metastasis Rev. 2021;40(4):1035–1053. doi: 10.1007/s10555-021-10011-5
   PubMed Web of Science ®Google Scholar
• Zatovicova M, Kajanova I, Barathova M, et al. Novel humanized monoclonal antibodies for targeting hypoxic human tumors via two distinct extracellular domains of carbonic anhydrase IX. Cancer Metab. 2022;10(1):3. doi: 10.1186/s40170-022-00279-8
   PubMed Web of Science ®Google Scholar
• Antal I, Koneracka M, Kubovcikova M, et al. Targeting of carbonic anhydrase IX-positive cancer cells by glycine-coated superparamagnetic nanoparticles. Colloids Surf B Biointerfaces. 2021;205:111893. DOI:10.1016/j.colsurfb.2021.111893
   PubMed Web of Science ®Google Scholar
• Kálosi A, Labudová M, Annušová A, et al. A bioconjugated MoS2 based nanoplatform with increased binding efficiency to cancer cells. Biomater Sci. 2020;8(7):1973–1980. doi: 10.1039/C9BM01975H
   PubMed Web of Science ®Google Scholar
• Bugárová N, Špitálsky Z, Mičušík M, et al. A multifunctional graphene oxide platform for targeting cancer. Cancers (Basel). 2019;11(6):753. doi: 10.3390/cancers11060753
   PubMed Web of Science ®Google Scholar
• Sheff JG, Kelly JF, Robotham A, et al. Hydrogen-deuterium exchange mass spectrometry reveals three unique binding responses of mAbs directed to the catalytic domain of hCAIX. MAbs. 2021;13(1):1997072. doi: 10.1080/19420862.2021.1997072
   PubMed Web of Science ®Google Scholar
• Lenferink AEG, Arabi GM, Rohani N, et al. Single domain antibodies targeting CA-IX as well as compositions comprising same. WO2022157714. 2022.
   Google Scholar
• Lenferink AEG, O’Connor M. High affinity monoclonal antibodies against cell surface expressed human carbonic anhydrase-IX (HCA-IX), and uses thereof. WO2019204939. 2019.
   Google Scholar
• Lenferink AEG, McDonald PC, Cantin C, et al. Isolation and characterization of monoclonal antibodies against human carbonic anhydrase-IX. MAbs. 2021;13(1):1999194. doi: 10.1080/19420862.2021.1999194
   PubMed Web of Science ®Google Scholar
• Testa C, Papini AM, Zeidler R, et al. First studies on tumor associated carbonic anhydrases IX and XII monoclonal antibodies conjugated to small molecule inhibitors. J Enzyme Inhib Med Chem. 2022;37(1):592–596. doi: 10.1080/14756366.2021.2004593
   PubMed Web of Science ®Google Scholar
• Battke C, Kremmer E, Mysliwietz J, et al. Generation and characterization of the first inhibitory antibody targeting tumour-associated carbonic anhydrase XII. Cancer Immunol Immunother. 2011;60(5):649–658. doi: 10.1007/s00262-011-0980-z
   PubMed Web of Science ®Google Scholar
• Zeidler R, Battke C, Flathey E, et al. Novel antibody to a carbonic anhydrase. 2011. WO2011138279
   Google Scholar
• Gondi G, Mysliwietz J, Hulikova A, et al. Antitumor efficacy of a monoclonal antibody that inhibits the activity of cancer-associated carbonic anhydrase XII. Cancer Res. 2013;73(21):6494–6503. doi: 10.1158/0008-5472.CAN-13-1110
   PubMed Web of Science ®Google Scholar
• Fiedler L, Kellner M, Gosewisch A, et al. Evaluation of 177Lu[Lu]-CHX-A″-DTPA-6A10 Fab as a radioimmunotherapy agent targeting carbonic anhydrase XII. Nucl Med Biol. 2018;60:55–62. DOI:10.1016/j.nucmedbio.2018.02.004
   PubMed Web of Science ®Google Scholar
• von Neubeck B, Gondi G, Riganti C, et al. An inhibitory antibody targeting carbonic anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo. Int J Cancer. 2018;143(8):2065–2075. doi: 10.1002/ijc.31607
   PubMed Web of Science ®Google Scholar
• Alterio V, Kellner M, Esposito D, et al. Biochemical and structural insights into carbonic anhydrase xii/fab6a10 complex. J Mol Biol. 2019;431(24):4910–4921. doi: 10.1016/j.jmb.2019.10.022
   PubMed Web of Science ®Google Scholar
• Zeidler R. Novel Fab dimers. EP4119581. 2023.
   Google Scholar
• Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem. 2016;31(3):345–360. doi: 10.3109/14756366.2015.1122001
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbon- versus sulphur-based zinc binding groups for carbonic anhydrase inhibitors? J Enzyme Inhib Med Chem. 2018;33(1):485–495. doi: 10.1080/14756366.2018.1428572
   PubMed Web of Science ®Google Scholar
• Supuran CT. Experimental carbonic anhydrase inhibitors for the treatment of hypoxic tumors. J Exp Pharmacol. 2020;12:603–617. doi: 10.2147/JEP.S265620
   PubMedGoogle Scholar
• McDonald PC, Chia S, Bedard PL, et al. A Phase 1 Study of SLC-0111, a novel inhibitor of carbonic anhydrase ix, in patients with advanced solid tumors. Am J Clin Oncol. 2020;43(7):484–490. doi: 10.1097/COC.0000000000000691
   PubMed Web of Science ®Google Scholar
• Lolak N, Akocak S, Petreni A, et al. 1,3-Diaryl triazenes incorporating disulfonamides show effective inhibition of tumor-associated carbonic anhydrases IX and XII. Future Med Chem. 2023. in press.
   Google Scholar
• Tekeli T, Akocak S, Petreni A, et al. Potent carbonic anhydrase I, II, IX and XII inhibition activity of novel primary benzenesulfonamides incorporating bis-ureido moieties. J Enzyme Inhib Med Chem. 2023;38(1):2185762. doi: 10.1080/14756366.2023.2185762
   PubMed Web of Science ®Google Scholar
• Elimam DM, Eldehna WM, Salem R, et al. Natural inspired ligustrazine-based SLC-0111 analogues as novel carbonic anhydrase inhibitors. Eur J Med Chem. 2022;228:114008. DOI:10.1016/j.ejmech.2021.114008
   PubMed Web of Science ®Google Scholar
• Elbadawi MM, Eldehna WM, Nocentini A, et al. Development of 4-((3-oxo-3-phenylpropyl)amino)benzenesulfonamide derivatives utilizing tail/dual-tail approaches as novel carbonic anhydrase inhibitors. Eur J Med Chem. 2022 5;238:114412. doi: 10.1016/j.ejmech.2022.114412
   PubMed Web of Science ®Google Scholar
• Oudah KH, Mahmoud WR, Awadallah FM, et al. Design and synthesis of some new benzoylthioureido benzenesulfonamide derivatives and their analogues as carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem. 2023;38(1):12–23. doi: 10.1080/14756366.2022.2132485
   PubMed Web of Science ®Google Scholar
• Liguori F, Carradori S, Ronca R, et al. Benzenesulfonamides with different rigidity-conferring linkers as carbonic anhydrase inhibitors: an insight into the antiproliferative effect n glioblastoma, pancreatic, and breast cancer cells. J Enzyme Inhib Med Chem. 2022;37(1):1857–1869. doi: 10.1080/14756366.2022.2091557
   PubMed Web of Science ®Google Scholar
• Al-Warhi T, Elbadawi MM, Bonardi A, et al. Design and synthesis of benzothiazole-based SLC-0111 analogues as new inhibitors for the cancer-associated carbonic anhydrase isoforms IX and XII. J Enzyme Inhib Med Chem. 2022;37(1):2635–2643. doi: 10.1080/14756366.2022.2124409
   PubMed Web of Science ®Google Scholar
• Bozdag M, Carta F, Ceruso M, et al. Discovery of 4-Hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 analogues for the treatment of hypoxic tumors overexpressing carbonic anhydrase IX. J Med Chem. 2018;61(14):6328–6338. doi: 10.1021/acs.jmedchem.8b00770
   PubMed Web of Science ®Google Scholar
• Mboge MY, Combs J, Singh S, et al. Inhibition of carbonic anhydrase using slc-149: support for a noncatalytic function of caix in breast cancer. J Med Chem. 2021;64(3):1713–1724. doi: 10.1021/acs.jmedchem.0c02077
   PubMed Web of Science ®Google Scholar
• Zhang Z Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use. WO2017/004543, 2017.
   Google Scholar
• Kumar A, Siwach K, Supuran CT, et al. A decade of tail-approach based design of selective as well as potent tumor associated carbonic anhydrase inhibitors. Bioorg Chem. 2022;126:105920. DOI:10.1016/j.bioorg.2022.105920
   PubMed Web of Science ®Google Scholar
• Kumar A, Siwach K, Rom T, et al. Tail-approach based design and synthesis of Arylthiazolylhydrazono-1,2,3-triazoles incorporating sulfanilamide and metanilamide as human carbonic anhydrase I, II, IV and IX inhibitors. Bioorg Chem. 2022;123:105764. DOI:10.1016/j.bioorg.2022.105764
   PubMed Web of Science ®Google Scholar
• Allam HA, Albakry ME, Mahmoud WR, et al. Effect of hydrophobic extension of aryl enaminones and pyrazole-linked compounds combined with sulphonamide, sulfaguanidine, or carboxylic acid functionalities on carbonic anhydrase inhibitory potency and selectivity. J Enzyme Inhib Med Chem. 2023;38(1):2201403. doi: 10.1080/14756366.2023.2201403
   PubMed Web of Science ®Google Scholar
• Ivanova JN, Nocentini A, Tars K, et al. Atropo/Tropo flexibility: a tool for design and synthesis of self-adaptable inhibitors of carbonic anhydrases and their antiproliferative effect. J Med Chem. 2023;66(8):5703–5718. doi: 10.1021/acs.jmedchem.3c00007
   PubMed Web of Science ®Google Scholar
• Metwally HM, Abdelrasheed Allam H, Baselious F, et al. Arylidine extensions of 3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-benzenesulfonamide derivatives: synthesis, computational simulations and biological evaluation as tumor-associated carbonic anhydrase inhibitors. Bioorg Chem. 2023;135:106492. DOI:10.1016/j.bioorg.2023.106492
   PubMedGoogle Scholar
• Aboukhatwa SM, Sidhom PA, Angeli A, et al. Terminators or Guardians? design, synthesis, and cytotoxicity profiling of chalcone-sulfonamide hybrids. ACS Omega. 2023;8(8):7666–7683. doi: 10.1021/acsomega.2c07285
   PubMedGoogle Scholar
• Krymov SK, Scherbakov AM, Dezhenkova LG, et al. Indoline-5-sulfonamides: a role of the core in inhibition of cancer-related carbonic anhydrases, antiproliferative activity and circumventing of multidrug resistance. Pharmaceuticals (Basel). 2022;15(12):1453. doi: 10.3390/ph15121453
   PubMedGoogle Scholar
• El-Malah A, Taher ES, Angeli A, et al. Schiff bases as linker in the development of quinoline-sulfonamide hybrids as selective cancer-associated carbonic anhydrase isoforms IX/XII inhibitors: A new regioisomerism tactic. Bioorg Chem. 2023;131:106309. DOI:10.1016/j.bioorg.2022.106309
   PubMed Web of Science ®Google Scholar
• Vats L, Siwach K, Angeli A, et al. Tail approach synthesis of triazolylthiazolotriazole bearing benzenesulfonamides as carbonic anhydrase inhibitors capable of inducing apoptosis. Arch Pharm (Weinheim). 2023;356(2):e2200439. doi: 10.1002/ardp.202200439
   PubMed Web of Science ®Google Scholar
• Tawfik HO, Belal A, Abourehab MAS, et al. Dependence on linkers’ flexibility designed for benzenesulfonamides targeting discovery of novel hCA IX inhibitors as potent anticancer agents. J Enzyme Inhib Med Chem. 2022;37(1):2765–2785. doi: 10.1080/14756366.2022.2130285
   PubMed Web of Science ®Google Scholar
• Zain-Alabdeen AI, El-Moselhy TF, Sharafeldin N, et al. Synthesis and anticancer activity of new benzensulfonamides incorporating s-triazines as cyclic linkers for inhibition of carbonic anhydrase IX. Sci Rep. 2022;12(1):16756. doi: 10.1038/s41598-022-21024-7
   PubMed Web of Science ®Google Scholar
• Manzoor S, Angeli A, Zara S, et al. Development of benzene and benzothiazole-sulfonamide analogues as selective inhibitors of the tumor-associated carbonic anhydrase IX. Eur J Med Chem. 2022;243:114793. DOI:10.1016/j.ejmech.2022.114793
   PubMed Web of Science ®Google Scholar
• Thacker PS, Newaskar V, Angeli A, et al. Synthesis and biological evaluation of coumarin-thiazole hybrids as selective carbonic anhydrase IX and XII inhibitors. Arch Pharm (Weinheim). 2022;355(12):e2200232. doi: 10.1002/ardp.202200232
   PubMed Web of Science ®Google Scholar
• Abdel-Mohsen HT, Omar MA, Petreni A, et al. Novel 2-substituted thioquinazoline-benzenesulfonamide derivatives as carbonic anhydrase inhibitors with potential anticancer activity. Arch Pharm (Weinheim). 2022;355(12):e2200180. doi: 10.1002/ardp.202200180
   PubMed Web of Science ®Google Scholar
• Abdel-Mohsen HT, Petreni A, Supuran CT. Investigation of the carbonic anhydrase inhibitory activity of benzenesulfonamides incorporating substituted fused-pyrimidine tails. Arch Pharm (Weinheim). 2022;355(11):e2200274. doi: 10.1002/ardp.202200274
   PubMed Web of Science ®Google Scholar
• Yamali C, Sakagami H, Satoh K, et al. Investigation of carbonic anhydrase inhibitory effects and cytotoxicities of pyrazole-based hybrids carrying hydrazone and zinc-binding benzenesulfonamide pharmacophores. Bioorg Chem. 2022;127:105969. DOI:10.1016/j.bioorg.2022.105969
   PubMedGoogle Scholar
• Arrighi G, Puerta A, Petrini A, et al. Squaramide-tethered sulfonamides and coumarins: synthesis, inhibition of tumor-associated cas ix and xii and docking simulations. Int J Mol Sci. 2022;23(14):7685. doi: 10.3390/ijms23147685
   PubMed Web of Science ®Google Scholar
• Ivanova J, Nocentini A, Domraceva I, et al. 5-aryl or hetero-aryl substituted thiophen-2-sulphonamide derivatives as carbonic acid anhydrase inhibitors, synthesis thereof and antiproliferative effects. LV15699. 2023.
   Google Scholar
• Rössler SL, Grob NM, Buchwald SL, et al. Abiotic peptides as carriers of information for the encoding of small-molecule library synthesis. Science. 2023 Mar 3;379(6635):939–945. doi: 10.1126/science.adf1354
   PubMed Web of Science ®Google Scholar
• Nerella SG, Singh P, Thacker PS, et al. PET radiotracers and fluorescent probes for imaging human carbonic anhydrase IX and XII in hypoxic tumors. Bioorg Chem. 2023;133:106399. DOI:10.1016/j.bioorg.2023.106399
   PubMed Web of Science ®Google Scholar
• Rotermund A, Brandt S, Staege MS, et al. Differential CMS-related expression of cell surface carbonic anhydrases ix and xii in colorectal cancer models-implications for therapy. Int J Mol Sci. 2023;24(6):5797. doi: 10.3390/ijms24065797
   PubMed Web of Science ®Google Scholar
• Eloranta K, Pihlajoki M, Liljeström E, et al. SLC-0111, an inhibitor of carbonic anhydrase IX, attenuates hepatoblastoma cell viability and migration. Front Oncol. 2023;13:1118268.
   PubMed Web of Science ®Google Scholar
• Sarnella A, Ferrara Y, Albanese S, et al. Inhibition of bone marrow-mesenchymal stem cell-induced carbonic anhydrase ix potentiates chemotherapy efficacy in triple-negative breast cancer cells. Cells. 2023;12(2):298. doi: 10.3390/cells12020298
   PubMed Web of Science ®Google Scholar
• Yin L, Lu Y, Cao C, et al. CA9-related acidic microenvironment mediates cd8+ t cell related immunosuppression in pancreatic cancer. Front Oncol. 2022;11:832315. DOI:10.3389/fonc.2021.832315
   PubMed Web of Science ®Google Scholar
• Mussi S, Rezzola S, Chiodelli P, et al. Antiproliferative effects of sulphonamide carbonic anhydrase inhibitors C18, SLC-0111 and acetazolamide on bladder, glioblastoma and pancreatic cancer cell lines. J Enzyme Inhib Med Chem. 2022;37(1):280–286. doi: 10.1080/14756366.2021.2004592
   PubMed Web of Science ®Google Scholar
• Huo Z, Bilang R, Supuran CT, et al. Perfusion-Based bioreactor culture and isothermal microcalorimetry for preclinical drug testing with the carbonic anhydrase inhibitor slc-0111 in patient-derived neuroblastoma. Int J Mol Sci. 2022;23(6):3128. doi: 10.3390/ijms23063128
   PubMed Web of Science ®Google Scholar
• Sarnella A, Ferrara Y, Auletta L, et al. Inhibition of carbonic anhydrases IX/XII by SLC-0111 boosts cisplatin effects in hampering head and neck squamous carcinoma cell growth and invasion. J Exp Clin Cancer Res. 2022 Apr 2;41(1):122. doi: 10.1186/s13046-022-02345-x
   PubMed Web of Science ®Google Scholar
• Sufian MA, Zamanova S, Shabana AM, et al. Expression dynamics of ca ix epitope in cancer cells under intermittent hypoxia correlates with extracellular ph drop and cell killing by ureido-sulfonamide CA IX inhibitors. Int J Mol Sci. 2023;24(5):4595. doi: 10.3390/ijms24054595
   PubMed Web of Science ®Google Scholar
• Eldehna WM, El Hassab MA, Abdelshafi NA, et al. Development of potent nanosized carbonic anhydrase inhibitor for targeted therapy of hypoxic solid tumors. Int J Pharm. 2023;631:122537. DOI:10.1016/j.ijpharm.2022.122537
   PubMedGoogle Scholar
• Baglini E, Ravichandran R, Berrino E, et al. Tetrahydroquinazole-based secondary sulphonamides as carbonic anhydrase inhibitors: synthesis, biological evaluation against isoforms I, II, IV, and IX, and computational studies. J Enzyme Inhib Med Chem. 2021;36(1):1874–1883. doi: 10.1080/14756366.2021.1956913
   PubMed Web of Science ®Google Scholar
• Salerno S, Amendola G, Angeli A, et al. Inhibition studies on carbonic anhydrase isoforms I, II, IV and IX with N-arylsubstituted secondary sulfonamides featuring a bicyclic tetrahydroindazole scaffold. Eur J Med Chem. 2021;220:113490. DOI:10.1016/j.ejmech.2021.113490
   PubMed Web of Science ®Google Scholar
• Abdoli M, Luca V, Capasso C, et al. Investigation of carbonic anhydrase inhibitory potency of (Z/E)-alkyl N’-benzyl-N-(arylsulfonyl)-carbamimidothioates. Future Med Chem. 2023;15(7):615–627. doi: 10.4155/fmc-2022-0287
   PubMed Web of Science ®Google Scholar
• Abdoli M, De Luca V, Capasso C, et al. Inhibition studies on carbonic anhydrase isoforms I, II, IX, and XII with a series of sulfaguanidines. ChemMedchem. 2023;18(6):e202200658. doi: 10.1002/cmdc.202200658
   PubMed Web of Science ®Google Scholar
• Abdelgawad MA, Bukhari SNA, Musa A, et al. New sulfamethoxazole derivatives as selective carbonic anhydrase ix and xii inhibitors: design, synthesis, cytotoxic activity and molecular modeling. Pharmaceuticals (Basel). 2022;15(9):1134. doi: 10.3390/ph15091134
   PubMedGoogle Scholar
• Briganti F, Pierattelli R, Scozzafava A, et al. Carbonic anhydrase inhibitors. Part 37. Novel classes of carbonic anhydrase inhibitors and their interaction with the native and cobalt-substituted enzyme: kinetic and spectroscopic investigations. Eur J Med Chem. 1996;31(12):1001–1010. doi: 10.1016/S0223-5234(97)86179-X
   Web of Science ®Google Scholar
• Elsayed ZM, Almahli H, Nocentini A, et al. Development of novel anilinoquinazoline-based carboxylic acids as non-classical carbonic anhydrase IX and XII inhibitors. J Enzyme Inhib Med Chem. 2023;38(1):2191163. doi: 10.1080/14756366.2023.2191163
   PubMed Web of Science ®Google Scholar
• Pontecorvi V, Mori M, Picarazzi F, et al. Novel insights on human carbonic anhydrase inhibitors based on coumalic acid: design, synthesis, molecular modeling investigation, and biological studies. Int J Mol Sci. 2022;23(14):7950. doi: 10.3390/ijms23147950
   PubMed Web of Science ®Google Scholar
• Langella E, D’Ambrosio K, D’Ascenzio M, et al. A combined crystallographic and theoretical study explains the capability of carboxylic acids to adopt multiple binding modes in the active site of carbonic anhydrases. Chemistry. 2016;22(1):97–100. doi: 10.1002/chem.201503748
   PubMed Web of Science ®Google Scholar
• De Simone G, Supuran CT. (In)organic anions as carbonic anhydrase inhibitors. J Inorg Biochem. 2012;111:117–129. doi: 10.1016/j.jinorgbio.2011.11.017
   PubMed Web of Science ®Google Scholar
• Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc. 2009;131(8):3057–3062. doi: 10.1021/ja809683v
   PubMed Web of Science ®Google Scholar
• D’Ambrosio K, Carradori S, Monti SM, et al. Out of the active site binding pocket for carbonic anhydrase inhibitors. Chem Commun (Camb). 2015;51(2):302–305. doi: 10.1039/C4CC07320G
   PubMed Web of Science ®Google Scholar
• Astrain-Redin N, Paoletti N, Plano D, et al. Selenium-analogs based on natural sources as cancer-associated carbonic anhydrase isoforms IX and XII inhibitors. J Enzyme Inhib Med Chem. 2023;38(1):2191165. doi: 10.1080/14756366.2023.2191165
   PubMed Web of Science ®Google Scholar
• Angeli A, Tanini D, Nocentini A, et al. Selenols: a new class of carbonic anhydrase inhibitors. Chem Commun (Camb). 2019;55(5):648–651. doi: 10.1039/C8CC08562E
   PubMed Web of Science ®Google Scholar
• Tanini D, Capperucci A, Ferraroni M, et al. Direct and straightforward access to substituted alkyl selenols as novel carbonic anhydrase inhibitors. Eur J Med Chem. 2020;185:111811. DOI:10.1016/j.ejmech.2019.111811
   PubMed Web of Science ®Google Scholar
• Petreni A, Iacobescu A, Simionescu N, et al. Carbonic anhydrase inhibitors bearing organotelluride moieties as novel agents for antitumor therapy. Eur J Med Chem. 2022;244:114811. DOI:10.1016/j.ejmech.2022.114811
   PubMed Web of Science ®Google Scholar
• Gumus A, Bozdag M, Akdemir A, et al. Thiosemicarbazide-substituted coumarins as selective inhibitors of the tumor associated human carbonic anhydrases IX and XII. Molecules. 2022;27(14):4610. doi: 10.3390/molecules27144610
   PubMed Web of Science ®Google Scholar
• Zengin Kurt B, Celebi G, Ozturk Civelek D, et al. Tail-approach-based design and synthesis of coumarin-monoterpenes as carbonic anhydrase inhibitors and anticancer agents. ACS Omega. 2023;8(6):5787–5807. doi: 10.1021/acsomega.2c07459
   PubMedGoogle Scholar
• Mahammad Ghouse S, Bahatam K, Angeli A, et al. Synthesis and biological evaluation of new 3-substituted coumarin derivatives as selective inhibitors of human carbonic anhydrase IX and XII. J Enzyme Inhib Med Chem. 2023;38(1):2185760. doi: 10.1080/14756366.2023.2185760
   PubMed Web of Science ®Google Scholar
• Sethi A, Munagalasetty S, Arifuddin M, et al. Coumarin and piperazine conjugates as selective inhibitors of the tumor-associated carbonic anhydrase IX and XII isoforms. Anticancer Agents Med Chem. 2023;23(10):1184–1191. doi: 10.2174/1871520623666230202123535
   PubMed Web of Science ®Google Scholar
• Ibrahim HS, Abdelrahman MA, Nocentini A, et al. Insights into the effect of elaborating coumarin-based aryl enaminones with sulfonamide or carboxylic acid functionality on carbonic anhydrase inhibitory potency and selectivity. Bioorg Chem. 2022;126:105888. DOI:10.1016/j.bioorg.2022.105888
   PubMed Web of Science ®Google Scholar
• Chu N, Wang Y, Jia H, et al. Design, synthesis and biological evaluation of new carbohydrate-based coumarin derivatives as selective carbonic anhydrase ix inhibitors via “click. React Molecules. 2022;27(17):5464. doi: 10.3390/molecules27175464
   PubMed Web of Science ®Google Scholar
• El-Damasy AK, Kim HJ, Nocentini A, et al. Discovery of new 6-ureido/amidocoumarins as highly potent and selective inhibitors for the tumour-relevant carbonic anhydrases IX and XII. J Enzyme Inhib Med Chem. 2023;38(1):2154603. doi: 10.1080/14756366.2022.2154603
   PubMed Web of Science ®Google Scholar
• Ivanova J, Abdoli M, Nocentini A, et al. Derivatives of 4-methyl-1,2,3-benzoxathiazine 2,2-dioxide as selective inhibitors of human carbonic anhydrases IX and XII over the cytosolic isoforms I and II. J Enzyme Inhib Med Chem. 2023;38(1):2170370. doi: 10.1080/14756366.2023.2170370
   PubMed Web of Science ®Google Scholar
• Ivanova J, Abdoli M, Nocentini A, et al. 1,2,3-2, benzoxathiazine-2-dioxides - effective inhibitors of human carbonic anhydrases. J Enzyme Inhib Med Chem. 2023;38(1):225–238. doi: 10.1080/14756366.2022.2142787
   PubMed Web of Science ®Google Scholar
• Pustenko A, Balašova A, Nocentini A, et al. 3H-1,2-benzoxaphosphepine 2-oxides as selective inhibitors of carbonic anhydrase IX and XII. J Enzyme Inhib Med Chem. 2023;38(1):216–224. doi: 10.1080/14756366.2022.2143496
   PubMed Web of Science ®Google Scholar
• Grandane A, Domraceva I, Supuran CT, et al. Derivatives of oxathiino[6,5-B]pyridine 2,2-dioxide as inhibitors of carbonic anhydrases, their synthesis and anti-cancer effect. LV15498. 2020.
   Google Scholar
• Giovannuzzi S, Capasso C, Nocentini A, et al. Continued structural exploration of sulfocoumarin as selective inhibitor of tumor-associated human carbonic anhydrases ix and XII. Molecules. 2022;27(13):4076. doi: 10.3390/molecules27134076
   PubMed Web of Science ®Google Scholar
• Angeli A, Supuran CT. Click chemistry approaches for developing carbonic anhydrase inhibitors and their applications. J Enzyme Inhib Med Chem. 2023;38(1):2166503. doi: 10.1080/14756366.2023.2166503
   PubMed Web of Science ®Google Scholar
• Tars K, Vullo D, Kazaks A, et al. Sulfocoumarins (1,2-benzoxathiine-2,2-dioxides): a class of potent and isoform-selective inhibitors of tumor-associated carbonic anhydrases. J Med Chem. 2013;56(1):293–300. doi: 10.1021/jm301625s
   PubMed Web of Science ®Google Scholar
• Huwaimel BI, Jonnalagadda SK, Jonnalagadda S, et al. Selective carbonic anhydrase IX and XII inhibitors based around a functionalized coumarin scaffold. Drug Dev Res. 2023;84(4):681–702. in press. doi: 10.1002/ddr.22049
   PubMed Web of Science ®Google Scholar
• Supuran CT. Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders. J Enzyme Inhib Med Chem. 2021;36(1):1702–1714. doi: 10.1080/14756366.2021.1945049
   PubMed Web of Science ®Google Scholar
• Tinivella A, Nwachukwu JC, Angeli A, et al. Design, synthesis, biological evaluation and crystal structure determination of dual modulators of carbonic anhydrases and estrogen receptors. Eur J Med Chem. 2023;246:115011. DOI:10.1016/j.ejmech.2022.115011
   PubMed Web of Science ®Google Scholar
• Denner TC, Heise N, Zacharias J, et al. Small structural differences govern the carbonic anhydrase ii inhibition activity of cytotoxic triterpene acetazolamide conjugates. Molecules. 2023;28(3):1009. doi: 10.3390/molecules28031009
   PubMed Web of Science ®Google Scholar
• Braconi L, Teodori E, Riganti C, et al. New Dual P-Glycoprotein (P-gp) and Human Carbonic Anhydrase XII (hCA XII) Inhibitors as Multidrug Resistance (MDR) Reversers in Cancer Cells. J Med Chem. 2022;65(21):14655–14672. doi: 10.1021/acs.jmedchem.2c01175
   PubMed Web of Science ®Google Scholar
• Agamennone M, Fantacuzzi M, Carradori S, et al. Coumarin-based dual inhibitors of human carbonic anhydrases and monoamine oxidases featuring amino acyl and (pseudo)-dipeptidyl appendages: in vitro and computational studies. Molecules. 2022;27(22):7884. doi: 10.3390/molecules27227884
   PubMed Web of Science ®Google Scholar
• Bonardi A, Micheli L, Di Cesare Mannelli L, et al. Development of hydrogen sulfide-releasing carbonic anhydrases ix- and xii-selective inhibitors with enhanced antihyperalgesic action in a rat model of arthritis. J Med Chem. 2022;65(19):13143–13157. doi: 10.1021/acs.jmedchem.2c00982
   PubMed Web of Science ®Google Scholar
• Giustarini D, Tazzari V, Bassanini I, et al. The new H 2 S-releasing compound ACS94 exerts protective effects through the modulation of thiol homoeostasis. J Enzyme Inhib Med Chem. 2018;33(1):1392–1404. doi: 10.1080/14756366.2018.1509211
   PubMed Web of Science ®Google Scholar
• Zhu Y, Archer WR, Morales KF, et al. Enzyme-triggered chemodynamic therapy via a peptide-h 2 s donor conjugate with complexed fe 2+. Angew Chem Int Ed Engl. 2023;62(22):e202302303. in press. doi: 10.1002/anie.202302303
   PubMedGoogle Scholar
• Shaldam MA, Almahli H, Angeli A, et al. Discovery of sulfonamide-tethered isatin derivatives as novel anticancer agents and VEGFR-2 inhibitors. J Enzyme Inhib Med Chem. 2023 Dec;38(1):2203389. doi: 10.1080/14756366.2023.2203389
   PubMed Web of Science ®Google Scholar
• Boyd NH, Walker K, Fried J, et al. Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. JCI Insight. 2017;2(24):e92928. doi: 10.1172/jci.insight.92928
   PubMed Web of Science ®Google Scholar
• Kim JH, Park S, Jung E, et al. A dual-action niclosamide-based prodrug that targets cancer stem cells and inhibits TNBC metastasis. Proc Natl Acad Sci U S A. 2023;120(21):e2304081120. doi: 10.1073/pnas.2304081120
   PubMed Web of Science ®Google Scholar
• Giovannuzzi S, Bonardi A, Gratteri P, et al. Discovery of the first-in-class potent and isoform-selective human carbonic anhydrase III inhibitors. J Enzyme Inhib Med Chem. 2023;38(1):2202360. doi: 10.1080/14756366.2023.2202360
   PubMed Web of Science ®Google Scholar
• Nocentini A, Angeli A, Carta F, et al. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J Enzyme Inhib Med Chem. 2021;36(1):561–580. doi: 10.1080/14756366.2021.1882453
   PubMed Web of Science ®Google Scholar
• Supuran CT. A simple yet multifaceted 90 years old, evergreen enzyme: carbonic anhydrase, its inhibition and activation. Bioorg Med Chem Lett. 2023;93:129411. doi: 10.1016/j.bmcl.2023.129411
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li ZX, Zhu YJ, et al. Single-cell transcriptome analysis uncovers intratumoral heterogeneity and underlying mechanisms for drug resistance in hepatobiliary tumor organoids. Adv Sci. 2021;8(11):e2003897. doi: 10.1002/advs.202003897
   Web of Science ®Google Scholar
• Na JC, Kim JH, Kim SY, et al. Establishment of patient-derived three-dimensional organoid culture in renal cell carcinoma. Investig Clin Urol. 2020;61(2):216–223. doi: 10.4111/icu.2020.61.2.216
   PubMed Web of Science ®Google Scholar
• Peerzada MN, Hamel E, Bai R, et al. Deciphering the key heterocyclic scaffolds in targeting microtubules, kinases and carbonic anhydrases for cancer drug development. Pharmacol Ther. 2021;225:107860. DOI:10.1016/j.pharmthera.2021.107860
   PubMed Web of Science ®Google Scholar
• Elsawi AE, Elbadawi MM, Nocentini A, et al. 1, 5-diaryl-1,2,4-triazole ureas as new slc-0111 analogues endowed with dual carbonic anhydrase and vegfr-2 inhibitory activities. J Med Chem. 2023. in press. doi: 10.1021/acs.jmedchem.3c00721
   PubMed Web of Science ®Google Scholar
• Ismail RSM, El Kerdawy AM, Soliman DH, et al. Discovery of a new potent oxindole multi-kinase inhibitor among a series of designed 3-alkenyl-oxindoles with ancillary carbonic anhydrase inhibitory activity as antiproliferative agents. BMC Chem. 2023;17(1):81. doi: 10.1186/s13065-023-00994-3
   PubMed Web of Science ®Google Scholar
• Abbate F, Winum JY, Potter BV, et al. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorg Med Chem Lett. 2004;14(1):231–234. doi: 10.1016/j.bmcl.2003.09.064
   PubMed Web of Science ®Google Scholar